












ORIGINAL RESEARCH

Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study

Maya H Buch ^{1,2}, Daniel Aletaha ³, Bernard G Combe ⁴, Yoshiya Tanaka ⁵, Roberto Caporali ^{6,7}, Hendrik Schulze-Koops ⁸, Tsutomu Takeuchi ^{9,10}, Jacques-Eric Gottenberg ¹¹, Ricardo Blanco ¹², Patrick Verschueren ¹³, Anna Zubrzycka-Sienkiewicz¹⁴, Francesco De Leonardis¹⁵, Edmund V Erika Omoruyi¹⁶, Vijay Rajendran¹⁶, Paul Emery ^{17,18}

To cite: Buch MH, Aletaha D, Combe BG, *et al.* Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study. *RMD Open* 2024;**12**:e004476. doi:10.1136/rmdopen-2024-004476

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/rmdopen-2024-004476>).

Received 30 April 2024
Accepted 24 August 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Professor Maya H Buch;
maya.buch@manchester.ac.uk

ABSTRACT

Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs. Filgotinib is a Janus kinase 1-preferential inhibitor available in two doses for moderate-to-severe RA. We report the long-term efficacy and safety of filgotinib.

Methods In the ongoing long-term extension study FINCH 4 (NCT03025308), patients continue filgotinib 200 mg or 100 mg from FINCH 1, 2 or 3 or receive filgotinib 200 mg or 100 mg de novo. Efficacy assessments up to week 156 include American College of Rheumatology 20% response (ACR20), Disease Activity Score 28 using C-reactive protein of <2.6, Clinical Disease Activity Index of ≤2.8, Simplified Disease Activity Index of ≤3.3 and Boolean remission (1.0 and 2.0) with non-responder imputation.

Results In patients with an inadequate response to methotrexate, 60.2% and 54.6% receiving de novo filgotinib 200 mg and 100 mg had an ACR20 at week 156, respectively, as did 67.3% and 59.5% of those who continued filgotinib 200 mg and 100 mg. At week 156, Boolean remission 1.0 was achieved by 18.8% and 15.4% of patients treated with de novo filgotinib 200 mg and 100 mg, respectively, and by 21.1% and 18.5% when Boolean 2.0 criteria were applied. Similar efficacy data were seen in patients from FINCH 2 and 3. Safety data were consistent with the known safety profile of filgotinib.

Conclusion In FINCH 4, filgotinib 200 mg and 100 mg (continuous or de novo) demonstrated sustained efficacy up to week 156 in patients enrolled from FINCH 1, 2 or 3, with no unexpected safety results.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by inflammation of the joints, substantial pain and decreased

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ The preferential Janus kinase 1 inhibitor filgotinib demonstrated efficacy and was generally well tolerated in patients with rheumatoid arthritis (RA) in phase 3 randomised controlled trials (FINCH 1–3).

WHAT THIS STUDY ADDS

⇒ Results from the long-term extension study FINCH 4 showed filgotinib 200 mg and 100 mg continued to demonstrate efficacy, as assessed by a range of measures including American College of Rheumatology 20%/50%/70% responses, Clinical Disease Activity Index, Disease Activity Score 28 using C-reactive protein, Simplified Disease Activity Index and Boolean 1.0 and 2.0 remission. The safety data observed during the long-term extension were in line with the known safety profile for filgotinib.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ These findings provide clinicians with evidence that filgotinib can continue to provide long-term clinical benefits to patients with RA.

quality of life.^{1 2} Current recommendations advocate a treat-to-target approach, whereby treatment is adjusted until the treatment goal—usually sustained remission or low disease activity—is achieved.^{3 4} The initial treatment with conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate, is recommended as soon as the diagnosis is confirmed. If the treatment target is not reached, depending on the patient's risk profile, other csDMARDs should be considered or a biologic (b) DMARD or targeted synthetic (ts) DMARD included.^{3 4}

Filgotinib is a preferential Janus kinase (JAK) 1 inhibitor, available in two doses (100 mg and 200 mg daily), for the treatment of moderate-to-severe RA in adult patients who have responded inadequately or are intolerant to one or more csDMARDs.⁵ Filgotinib was evaluated in FINCH 1–3 studies, which were phase 3 randomised controlled trials conducted in methotrexate-naïve patients (FINCH 3) and in those with an inadequate response to methotrexate (FINCH 1) or bDMARDs (FINCH 2).^{6–8} Each study met its primary endpoint by demonstrating that a significantly greater proportion of patients treated with filgotinib achieved American College of Rheumatology 20% response (ACR20) compared with those treated with either placebo at week 12 (FINCH 1 and 2) or methotrexate at week 24 (FINCH 3).^{6–8} In addition, other endpoints associated with signs and symptoms of RA improved with filgotinib treatment.^{6–8} In the RA clinical trial programme, filgotinib was generally well tolerated.⁹ To evaluate the long-term efficacy and safety of filgotinib, patients completing treatment in FINCH 1, 2 or 3 could participate in FINCH 4, a long-term extension study. In the current analysis, we report interim efficacy, safety and patient-reported outcomes up to week 156 of FINCH 4. Given that the Boolean 2.0 criteria were recently validated,¹⁰ Boolean 2.0 remission is reported as an exploratory objective. Further data will be reported upon study completion.

METHODS

Study design

FINCH 4 (NCT03025308) is an ongoing, phase 3, open-label, long-term extension study. The primary outcome is safety and tolerability; the secondary outcome is efficacy. Eligible patients are adults with RA who completed one of the previous phase 3 randomised controlled trials of filgotinib: FINCH 1 (NCT02889796), FINCH 2 (NCT02873936) or FINCH 3 (NCT02886728). As previously reported, FINCH 1 was a 52-week study in which patients with an inadequate response to methotrexate (methotrexate-IR) received filgotinib 100 mg, filgotinib 200 mg, adalimumab or placebo, each with methotrexate.⁶ FINCH 2 was a 24-week study in which patients with an inadequate response to bDMARDs (bDMARD-IR) received filgotinib 100 mg, filgotinib 200 mg or placebo (each with one or two protocol-specified csDMARDs).⁷ FINCH 3 was a 52-week study in which patients who were methotrexate naïve received filgotinib 200 mg, methotrexate or filgotinib 100 mg or 200 mg with methotrexate.⁸ In FINCH 4, patients are being treated with filgotinib 100 mg or 200 mg for up to 6 years (online supplemental figure 1). In FINCH 4, patients can continue to receive csDMARDs that were permitted in the parent study, with the exception of patients from FINCH 3, who undergo a 4-week methotrexate wash-out period before inclusion in FINCH 4.

The trial was conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation Good Clinical Practice guidelines. FINCH 1 was approved by the Advarra Central Institutional Review Board (Reference # 00000971). FINCH 2 was approved by the Administrative Panel on Human Subjects in Medical Research (Reference # 4593). FINCH 3 was approved by the Ethics Committee Research UZ/KU Leuven (Reference # S59627). The study protocol was approved by the international review board or ethics committee at each study site, and all patients provided written informed consent.

Assessments

Efficacy of filgotinib 100 mg and 200 mg was assessed according to previous filgotinib exposure in the parent studies: patients either received de novo filgotinib in FINCH 4, having been re-randomised to filgotinib from adalimumab in FINCH 1, placebo in FINCH 2 or methotrexate in FINCH 3 or continued to receive filgotinib in FINCH 4, having been treated in a filgotinib arm during the parent study. Patients in FINCH 1, who initially received placebo and were re-randomised to filgotinib 100 mg or 200 mg at week 24, were included in the subgroup of patients who continued to receive filgotinib.

Efficacy of filgotinib 100 mg and 200 mg was assessed by measuring the proportion of patients to achieve the following outcomes at weeks 2, 6, 12 and then every 12 weeks up to week 156 of the long-term extension: ACR20, ACR50 and ACR70 (calculated using the baseline values of the parent study), Disease Activity Score 28 using C-reactive protein (DAS28-CRP) of <2.6, Clinical Disease Activity Index (CDAI) of ≤2.8, Simplified Disease Activity Index (SDAI) of ≤3.3, Boolean remission 1.0 and Boolean remission 2.0 (the threshold for patient global assessment in Boolean 2.0 remission is increased from 1 cm to 2 cm on a 10-cm visual analogue scale [VAS]¹⁰). In addition, changes from baseline in patient-reported pain (measured using a VAS) and Health Assessment Questionnaire–Disability Index (HAQ-DI) were assessed.

To assess the safety of filgotinib, the exposure-adjusted incidence rate (EAIR) of treatment-emergent adverse events (TEAEs) per 100 patient-years of exposure was calculated. The 95% CI of the EAIR was calculated based on Poisson distribution.¹¹ EAIRs of TEAEs are reported based on filgotinib dose and according to previous filgotinib exposure in parent studies. TEAEs were defined as any adverse events that began on or after the study drug start date, up to 30 days post-permanent discontinuation of the study drug. If a TEAE was reported multiple times for a patient (with different start and end dates) in the same treatment period, the onset of the first TEAE occurrence was used for EAIR analysis. The severity of TEAEs was graded using the modified Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. If a CTCAE criterion did not exist, the investigator used the following grades to describe the maximum intensity of the adverse event: Grade 1

(mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening) or Grade 5 (fatal). A serious TEAE was defined as an event resulting in death, in-patient hospitalisation or prolongation of existing hospitalisation; persistent or significant disability/incapacity; life-threatening events; a congenital anomaly/birth defect; or a medically important event or reaction that may jeopardise the patient or require intervention to prevent one of the other serious TEAEs described. The investigator or qualified sub-investigator was responsible for determining whether TEAEs were related to the study drug based on their clinical judgement.

Statistical analysis

The primary analysis set for safety and efficacy is the safety analysis set, which included all enrolled patients who received at least one dose of filgotinib in FINCH 4. Non-responder imputation (NRI) was performed for binary efficacy outcomes (ACR20, ACR50, ACR70, DAS28-CRP <2.6, CDAI ≤2.8, SDAI ≤3.3 and Boolean remission [1.0 and 2.0]), under which patients with missing outcomes were classified as non-responders. In addition, observed case (OC) analyses were performed.

RESULTS

Baseline characteristics and filgotinib exposure

In total, 2729 patients were included in the analysis. As of 6 May 2022, 1723 of these patients (63.1%) were still receiving the study drug and 1006 (36.9%) had prematurely discontinued the study drug. The reasons for discontinuations are shown in online supplemental table 1. At FINCH 4 baseline, the mean (SD) age was 54 (12.9) years, mean (SD) body mass index was 27.9 (6.32) mg/kg² and 80.5% of patients were female. The median (IQR) duration of RA was 4.3 (1.7–9.9) years (table 1). Approximately half of patients in FINCH 4 (51.3%) were methotrexate-IR (from FINCH 1), 13.6% were bDMARD-IR (from FINCH 2) and 35.2% were methotrexate naïve (from FINCH 3) at inclusion in the parent study. Median (IQR) exposure to filgotinib during FINCH 4 was 205.6 (162.0–229.7) weeks (online supplemental table 2).

ACR responses and disease activity measures

Based on the NRI analysis, of methotrexate-IR patients (from FINCH 1) who continued to receive filgotinib 200 mg and 100 mg in FINCH 4, 91.9% and 90.4%, respectively, had an ACR20 from baseline of FINCH 1 to baseline of FINCH 4, as did 67.3% and 59.5%, respectively, from baseline of FINCH 1 to week 156 of FINCH 4. In patients who received de novo filgotinib 200 mg and 100 mg in FINCH 4, 91.4% and 88.5%, respectively, had an ACR20 from FINCH 1 baseline to FINCH 4 baseline, as did 60.2% and 54.6%, respectively, from FINCH 1 baseline to week 156 of FINCH 4 (figure 1A). Based on the OC analysis, 93.0% and 84.3% of patients who continued to receive filgotinib 200 mg and 100 mg had an ACR20 at week 156,

as did 90.6% and 85.5% of the filgotinib 200 mg and 100 mg de novo group, respectively (online supplemental figure 2A).

The NRI analysis showed that of bDMARD-IR patients (from FINCH 2) who continued to receive filgotinib 200 mg and 100 mg in FINCH 4, 75.8% and 66.9%, respectively, had an ACR20 from baseline of FINCH 2 to baseline of FINCH 4, decreasing to 53.8% and 48.4%, respectively, from baseline of FINCH 2 to week 156 of FINCH 4. In patients who received placebo in FINCH 2 and received de novo filgotinib 200 mg and 100 mg in FINCH 4, 40.7% and 49.1%, respectively, had an ACR20 from FINCH 2 baseline to FINCH 4 baseline, as did 45.8% and 47.3%, respectively, from FINCH 2 baseline to week 156 of FINCH 4 (figure 1B). Based on the OC analysis, 89.9% and 83.3% of patients who continued to receive filgotinib 200 mg and 100 mg, respectively, had an ACR20 at week 156, as did 73.0% and 70.3% of the filgotinib 200 mg and 100 mg de novo group, respectively (online supplemental figure 2B).

According to NRI analysis, in methotrexate-naïve patients (from FINCH 3) the proportion of patients with ACR20 from FINCH 3 baseline decreased from FINCH 4 baseline to week 156 in those continuing filgotinib treatment (93.3% to 58.5% for filgotinib 200 mg; 87.0% to 50.9% for filgotinib 100 mg) and in the de novo group (83.1% to 58.1% for filgotinib 200 mg; 84.1% to 57.6% for filgotinib 100 mg; figure 1C). Based on the OC analysis, 93.8% and 86.9% of patients who continued to receive filgotinib 200 mg and 100 mg, respectively, had an ACR20 at week 156, as did 87.8% and 87.9% of the filgotinib 200 mg and 100 mg de novo group, respectively (online supplemental figure 2C). Similar trends were observed when ACR50 and ACR70 were assessed in the NRI analysis (online supplemental figures 3 and 4) and OC analysis (online supplemental figures 5 and 6).

Of methotrexate-IR patients who continued to receive filgotinib 200 mg and 100 mg in FINCH 4, 60.2% and 52.8%, respectively, had achieved DAS28-CRP of <2.6 at FINCH 4 baseline (NRI analysis), as had 44.3% and 37.9% respectively, at week 156 of FINCH 4. In those who received de novo filgotinib 200 mg and 100 mg, 60.2% and 53.8%, respectively, achieved DAS28-CRP of <2.6 at FINCH 4 baseline, as did 39.1% and 29.2%, respectively, at week 156 (figure 2A). Of bDMARD-IR patients who continued to receive filgotinib 200 mg and 100 mg in FINCH 4, 34.8% and 29.8%, respectively, achieved DAS28-CRP of <2.6 at FINCH 4 baseline, as did 31.8% and 25.0%, respectively, at week 156. Of those receiving de novo filgotinib 200 mg and 100 mg, 13.6% and 18.2% achieved DAS28-CRP of <2.6 at FINCH 4 baseline, as did 25.4% and 21.8%, respectively, at week 156 (figure 2B). In methotrexate-naïve patients who continued to receive filgotinib 200 mg and 100 mg, 61.8% and 50.3% achieved DAS28-CRP of <2.6 at baseline of FINCH 4, respectively, as did 43.9% and 38.5% at week 156. In those who received de novo filgotinib 200 mg and 100 mg, 44.6% and 41.7%, respectively, achieved DAS28-CRP of <2.6 at

Table 1 Baseline characteristics at LTE baseline

	FIL200			FIL100		
	With continued FIL (n=1195)	With de novo FIL (n=335)	Total (n=1530)	With continued FIL (n=863)	With de novo FIL (n=336)	Total (n=1199)
Age (years), mean (SD)	53 (13.2)	54 (12.1)	53 (12.9)	54 (12.4)	55 (13.9)	54 (12.8)
Duration of RA from diagnosis (years)*						
Mean (SD)	6.7 (7.43)	6.9 (8.59)	6.7 (7.70)	8.5 (8.02)	6.8 (7.61)	8.0 (7.94)
Median (IQR)	3.8 (1.6–8.7)	3.5 (1.5–9.0)	3.8 (1.5–8.8)	5.7 (2.2–12.0)	4.0 (1.4–9.8)	5.1 (1.9–11.4)
Female, n (%)	960 (80.3)	267 (79.7)	1227 (80.2)	699 (81.0)	272 (81.0)	971 (81.0)
Baseline BMI (kg/m ²), mean (SD)	27.9 (6.29)	27.9 (6.42)	27.9 (6.32)	27.9 (6.40)	27.9 (6.14)	27.9 (6.32)
Current smoker, n (%)	160 (13.4)	48 (14.3)	208 (13.6)	119 (13.8)	39 (11.6)	158 (13.2)
Parent study, n (%)						
FINCH 1	571 (47.8)	128 (38.2)	699 (45.7)	570 (66.0)	130 (38.7)	700 (58.4)
FINCH 2	132 (11.0)	59 (17.6)	191 (12.5)	124 (14.4)	55 (16.4)	179 (14.9)
FINCH 3	492 (41.2)	148 (44.2)	640 (41.8)	169 (19.6)	151 (44.9)	320 (26.7)
hsCRP (mg/L), mean (SD)	n=1194 40.90 (8.77)	n=335 70.53 (11.56)	n=1529 50.48 (9.51)	n=859 60.55 (11.20)	n=333 70.50 (12.45)	n=1192 60.82 (11.57)
DAS28-CRP, mean (SD)	n=1191 20.5 (1.08)	n=334 30.0 (1.27)	n=1525 20.6 (1.14)	n=855 20.8 (1.15)	n=333 20.9 (1.24)	n=1188 20.8 (1.18)
DAS28-CRP \leq 3.2, n (%)	919 (77.2)	208 (62.3)	1127 (73.9)	592 (69.2)	210 (63.1)	802 (67.5)
HAQ-DI, mean (SD)	n=1192 00.66 (0.62)	n=334 00.81 (0.65)	n=1526 00.69 (0.63)	n=861 00.78 (0.67)	n=336 00.84 (0.69)	n=1197 00.80 (0.68)
SDAI, mean (SD)	n=1190 70.6 (8.10)	n=334 110.0 (10.82)	n=1524 80.4 (8.87)	n=853 90.2 (8.96)	n=333 100.3 (10.19)	n=1186 90.5 (9.33)
CDAI, mean (SD)	n=1191 70.2 (7.90)	n=334 100.2 (10.38)	n=1525 70.8 (8.59)	n=857 80.5 (8.61)	n=336 90.6 (9.66)	n=1193 80.8 (8.93)
Patient's pain assessment (mm), mean (SD)	n=1191 23 (23.0)	n=334 29 (26.1)	n=1526 24 (23.8)	n=861 26 (23.8)	n=336 30 (26.8)	n=1197 27 (24.7)
Prior exposure to bDMARDs, n (%)	146 (12.2)	186 (55.5)	332 (21.7)	134 (15.5)	185 (55.1)	319 (26.6)
To adalimumab in FINCH 1	–	128 (38.2)	128 (8.4)	–	130 (38.7)	130 (10.8)

Continued

Table 1 Continued

	FIL200		FIL100				
	With continued FIL (n=1195)	With de novo FIL (n=335)	Total (n=1530)	With continued FIL (n=863)	With de novo FIL (n=336)	Total (n=1199)	Total (n=2729)
Concurrent oral CS on first dosing date, n (%)	471 (39.4)	146 (43.6)	617 (40.3)	395 (48.8)	130 (38.7)	525 (43.8)	1142 (41.8)
Concurrent methotrexate on first dosing date, n (%)	624 (52.2)	158 (47.2)	782 (51.1)	598 (69.3)	156 (46.4)	754 (62.9)	1536 (56.3)
Number of concurrent csDMARDs on first dosing date, n (%)							
0	504 (42.2)	154 (46.0)	658 (43.0)	230 (26.7)	154 (45.8)	384 (32.0)	1042 (38.2)
1	627 (52.5)	164 (49.0)	791 (51.7)	563 (65.2)	166 (49.4)	729 (60.8)	1520 (55.7)
≥2	64 (5.4)	17 (5.1)	81 (5.3)	70 (8.1)	16 (4.8)	86 (7.2)	167 (6.1)
Race, n (%)							
American Indian or Alaska Native	82 (6.9)	25 (7.5)	107 (7.0)	58 (6.7)	27 (8.0)	85 (7.1)	192 (7.0)
Asian	251 (21.0)	60 (17.9)	311 (20.3)	186 (21.6)	60 (17.9)	246 (20.5)	557 (20.4)
Black or African American	32 (2.7)	13 (3.9)	45 (2.9)	21 (2.4)	20 (6.0)	41 (3.4)	86 (3.2)
Native Hawaiian or Pacific Islander	1 (<0.1)	0	1 (<0.1)	0	0	0	1 (<0.1)
White	817 (68.4)	233 (69.6)	1050 (68.6)	585 (67.8)	226 (67.3)	811 (67.6)	1861 (68.2)
Other	11 (0.9)	3 (0.9)	14 (0.9)	12 (1.4)	3 (0.9)	15 (1.3)	29 (1.1)
Not reported	1 (<0.1)	1 (0.3)	2 (0.1)	1 (0.1)	0	1 (<0.1)	3 (0.1)
Ethnicity, n (%)							
Hispanic or Latino	221 (18.5)	69 (20.6)	290 (19.0)	150 (17.4)	72 (21.4)	222 (18.5)	512 (18.8)
Not Hispanic or Latino	968 (81.0)	265 (79.1)	1233 (80.6)	704 (81.6)	264 (78.6)	968 (80.7)	2201 (80.7)
Not reported	6 (0.5)	1 (0.3)	7 (0.5)	9 (1.0)	0	9 (0.8)	16 (0.6)
Concurrent medication use was defined as medications taken while a patient was receiving the study drug; patients started concurrent medication prior to the first dosing. Concurrent oral corticosteroid use on as-needed frequency was excluded from the mean oral corticosteroid daily dose.							
*Duration of RA (years) = (first dose date in LTE – date of initial diagnosis+1)/365.25.							
bDMARD, biologic disease-modifying anti-rheumatic drug; BMI, body mass index; CDAI, Clinical Disease Activity Index; CS, corticosteroid; csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; DAS28-CRP, Disease Activity Score 28 using C-reactive protein; FIL(100/200), filgotinib (100 mg/200 mg); HAQ-DI, Health Assessment Questionnaire-Disability Index; hsCRP, high-sensitivity C-reactive protein; LTE, long-term extension; RA, rheumatoid arthritis; SDAI, Simplified Disease Activity Index.							

Concurrent medication use was defined as medications taken while a patient was receiving the study drug; patients started concurrent medication prior to the first dosing. Concurrent oral corticosteroid use on as-needed frequency was excluded from the mean oral corticosteroid daily dose.

*Duration of RA (years) = (first dose date in LTE – date of initial diagnosis+1)/365.25.

Duration of RA (years) = (first dose date in LTE – date of initial diagnosis) + 1/365.25.




Figure 1 The proportion of patients who achieved ACR20 in FINCH 4 according to the parent study: FINCH 1 (A), FINCH 2 (B) and FINCH 3 (C) (safety analysis set, NRI). Patients with missing outcomes were set as non-responders. ACR20 was calculated based on the parent study baseline. Error bars show 95% CIs. ACR20, American College of Rheumatology 20% response; FIL(100/200), filgotinib (100 mg/200 mg); NRI, non-responder imputation.

FINCH 4 baseline, as did 41.9% and 39.7%, respectively, at week 156 (figure 2C). The proportion of patients to achieve DAS28-CRP of <2.6, based on the OC analysis, is presented in online supplemental figure 7.

In general, the proportion of patients achieving CDAI of ≤2.8 or SDAI of ≤3.3 remained constant in each subgroup (those continuing filgotinib and those

receiving de novo filgotinib) from FINCH 4 baseline to week 156 of FINCH 4, for each patient population (those from FINCH 1, 2 and 3); proportions were numerically slightly greater in the filgotinib 200 mg arm than in the filgotinib 100 mg arm in the NRI analyses (figure 3 and online supplemental figure 8) and OC analyses (online supplemental figures 9 and 10). For example,




Figure 2 The proportion of patients who achieved DAS28-CRP of <2.6 in FINCH 4 according to the parent study: FINCH 1 (A), FINCH 2 (B) and FINCH 3 (C) (safety analysis set, NRI). Patients with missing outcomes were set as non-responders. DAS28-CRP was calculated based on the parent study baseline. Error bars show 95% CIs. DAS28-CRP, Disease Activity Score 28 using C-reactive protein; FIL(100/200), filgotinib (100 mg/200 mg); NRI, non-responder imputation.

based on the NRI analysis, of methotrexate-IR patients who continued to receive filgotinib 200 mg and 100 mg in FINCH 4, 26.8% and 21.9%, respectively, achieved CDAI of ≤ 2.8 (remission) at week 156 (37.2% and 31.0%, respectively, in the OC analysis), as did 22.7% and 18.5%, respectively, of those receiving de novo filgotinib (33.7% and 29.3%, respectively, in the OC analysis (figure 3A and online supplemental figure 9A).

Patient-reported outcomes: pain and HAQ-DI

In methotrexate-IR patients, change from baseline (of the parent study) in pain and HAQ-DI remained constant to week 156 of FINCH 4 and was similar for both filgotinib doses and across subgroups (those continuing filgotinib vs those receiving de novo filgotinib [online supplemental figures 11A and 12A]). Among bDMARD-IR patients, in those receiving de




Figure 3 The proportion of patients who achieved CDAl of ≤ 2.8 in FINCH 4 according to the parent study: FINCH 1 (A), FINCH 2 (B) and FINCH 3 (C) (safety analysis set, NRI). Patients with missing outcomes were set as non-responders. Error bars show 95% CIs. CDAl, Clinical Disease Activity Index; FIL(100/200), filgotinib (100 mg/200 mg); NRI, non-responder imputation.

novo filgotinib, pain and HAQ-DI improved from FINCH 4 baseline to week 156; in those continuing to receive filgotinib, improvements in pain and HAQ-DI remained stable from FINCH 4 baseline to week 156 (online supplemental figures 11B and 12B). In methotrexate-naïve patients, changes from FINCH 4 baseline to week 156 were stable across subgroups (online supplemental figure 11C and 12C).

Boolean remission

In methotrexate-IR patients who continued filgotinib, the proportions achieving Boolean 1.0 remission at FINCH 4 baseline were 23.8% and 21.9% in the filgotinib 200 mg and 100 mg groups, respectively (NRI analysis). The proportions remained constant over the long-term extension, decreasing to 20.5% and 15.8% in the filgotinib 200 mg and 100 mg groups, respectively, at week 156 (NRI analysis; [figure 4A](#)). Similarly,




Figure 4 The proportion of patients who achieved Boolean remission 1.0 in FINCH 1 (A), FINCH 2 (B) and FINCH 3 (C) (safety analysis set, NRI). Patients with missing outcomes were set as non-responders. Error bars show 95% CIs. FIL(100/200), filgotinib (100 mg/200 mg); NRI, non-responder imputation.

the proportion of bDMARD-IR or methotrexate-naïve patients continuing filgotinib treatment (from FINCH 2 and 3, respectively), who achieved Boolean remission 1.0 at FINCH 4 baseline, generally remained constant up to week 156 for each filgotinib dose (NRI analysis; figure 4B,C).

Adopting Boolean 2.0 criteria slightly increased remission rates versus Boolean 1.0 criteria: for patients who continued filgotinib 200 mg and 100 mg, respectively, remission rates at week 156 increased by 4.2% and 4.9% in methotrexate-IR patients (figure 5A), by 1.5% and

2.4% in bDMARD-IR patients (figure 5B) and by 4.9% and 3.0% in methotrexate-naïve patients (figure 5C), as assessed using NRI.

In patients receiving de novo filgotinib in FINCH 4, remission rates were also numerically higher with Boolean 2.0 versus 1.0 criteria, and remission rates (using Boolean 1.0 or 2.0) were sustained up to week 156 of the long-term extension in all three patient populations (figures 4 and 5). Sustained remission rates were also observed in the OC analyses and were numerically higher with Boolean 2.0 versus 1.0 criteria (online supplemental figures 13 and 14).




Figure 5 The proportion of patients who achieved Boolean remission 2.0 in FINCH 1 (A), FINCH 2 (B) and FINCH 3 (C) (safety analysis set, NRI). Patients with missing outcomes were set as non-responders. Error bars show 95% CIs. FIL(100/200), filgotinib (100 mg/200 mg); NRI, non-responder imputation.

Safety

Safety data were obtained from 1530 patients with a total of 4591.2 patient-years of exposure (PYE) to filgotinib 200 mg (from FINCH 4 baseline) and 1199 patients with a total of 3553.8 PYE to filgotinib 100 mg (from FINCH 4 baseline). In the filgotinib 200 mg and 100 mg groups, respectively, the EAIR per 100 PYE (95% CI) was 93.7 (88.7–98.9) and 91.3 (85.8–97.1) for TEAEs; 7.0 (6.3–7.9) and 7.1 (6.2–8.1) for serious TEAEs; and 0.8 (0.6–1.2) and 0.5 (0.3–0.8) for TEAEs leading to death (table 2). The TEAEs leading to death are presented

in online supplemental table 3, and the TEAEs leading to premature discontinuation of the study drug are provided in online supplemental table 4. The EAIRs of TEAEs of interest, which comprised serious infections, herpes zoster, adjudicated major adverse cardiovascular events (MACE), adjudicated venous thromboembolic events, malignancies excluding non-melanoma skin cancer (NMSC) and NMSC, were comparable across treatment groups, regardless of prior exposure to filgotinib (table 2). When individual events within each of these categories were analysed, no discernible pattern

Table 2 Incidence and EAIR per 100 PYE of TEAEs in FINCH 4

	FIL200		FIL100	
	Number of patients (%) with the TEAE listed EAIR per 100 PYE (95% CI)		Number of patients (%) with the TEAE listed EAIR per 100 PYE (95% CI)	
	With continued FIL PYE=3572.7 (n=1195)	With de novo FIL PYE=1018.5 (n=335)	Total PYE=4591.2 (n=1530)	Total PYE=3553.8 (n=1199)
TEAE	1030 (86.19) 93.9 (88.3 to 99.9)	293 (87.46) 92.8 (82.4 to 104.0)	1323 (86.47) 93.7 (88.7 to 98.9)	743 (86.10) 96.0 (89.3 to 103.2)
Grade ≥3 TEAE	268 (22.43) 8.2 (7.3 to 9.3)	68 (20.30) 7.4 (5.7 to 9.3)	336 (21.96) 8.1 (7.2 to 9.0)	193 (22.36) 8.3 (7.2 to 9.6)
Serious TEAE	237 (19.83) 7.1 (6.2 to 8.1)	63 (18.81) 6.7 (5.2 to 8.6)	300 (19.61) 7.0 (6.3 to 7.9)	165 (19.12) 6.9 (5.9 to 8.1)
TEAE related to study drug	394 (32.97) 14.1 (12.8 to 15.6)	116 (34.63) 14.5 (12.0 to 17.4)	510 (33.33) 14.2 (13.0 to 15.5)	261 (30.24) 12.7 (11.2 to 14.4)
Grade ≥3 TEAE related to study drug	78 (6.53) 2.2 (1.8 to 2.8)	21 (6.27) 2.1 (1.3 to 3.2)	99 (6.47) 2.2 (1.8 to 2.7)	55 (6.37) 2.2 (1.6 to 2.8)
Serious TEAE related to study drug	67 (5.61) 1.9 (1.5 to 2.4)	16 (4.78) 1.6 (0.9 to 2.6)	83 (5.42) 1.8 (1.5 to 2.3)	37 (4.29) 1.5 (1.0 to 2.0)
TEAE leading to interruption of study drug	484 (50.5) 18.5 (16.9 to 20.2)	123 (36.72) 16.1 (13.4 to 19.3)	607 (39.67) 17.9 (16.5 to 19.4)	304 (35.23) 15.5 (13.8 to 17.4)
TEAE leading to premature discontinuation of study drug	128 (10.71) 3.6 (3.0 to 4.3)	36 (10.75) 3.6 (2.5 to 4.9)	164 (10.72) 3.6 (3.1 to 4.2)	95 (11.01) 3.7 (3.0 to 4.5)
TEAE leading to death	34 (2.85) 1.0 (0.7 to 1.3)	5 (1.49) 0.5 (0.2 to 1.1)	39 (2.55) 0.8 (0.6 to 1.2)	12 (1.39) 0.5 (0.2 to 0.8)
TEAEs of interest				
Serious infection	79 (6.61) 2.2 (1.8 to 2.8)	18 (5.37) 1.8 (1.1 to 2.8)	97 (6.34) 2.1 (1.7 to 2.6)	49 (5.68) 1.9 (1.4 to 2.6)
Herpes zoster	52 (4.35) 1.5 (1.1 to 2.0)	14 (4.18) 1.4 (0.8 to 2.4)	66 (4.31) 1.5 (1.1 to 1.9)	25 (2.90) 1.0 (0.6 to 1.5)
MACE (adjudicated)	16 (1.34) 0.4 (0.3 to 0.7)	1 (0.30) 0.1 (0.0 to 0.5)	17 (1.11) 0.4 (0.2 to 0.6)	10 (1.16) 0.4 (0.2 to 0.7)
VTE (adjudicated)	8 (0.67) 0.2 (0.1 to 0.4)	1 (0.30) 0.1 (0.0 to 0.5)	9 (0.59) 0.2 (0.1 to 0.4)	8 (0.93) 0.3 (0.1 to 0.6)
Malignancy (excluding NMSC)	29 (2.43) 0.8 (0.5 to 1.2)	13 (3.88) 1.3 (0.7 to 2.2)	42 (2.75) 0.9 (0.7 to 1.2)	20 (2.32) 0.8 (0.5 to 1.2)
NMSC	19 (1.59) 0.5 (0.3 to 0.8)	3 (0.90) 0.3 (0.1 to 0.9)	22 (1.44) 0.5 (0.3 to 0.7)	5 (0.58) 0.2 (0.1 to 0.5)

Continued

Table 2 Continued

	FIL200			FIL100		
	Number of patients (%) with the TEAE listed EAIR per 100 PYE (95% CI)			Number of patients (%) with the TEAE listed EAIR per 100 PYE (95% CI)		
	With continued FIL PYE=3572.7 (n=1195)	With de novo FIL PYE=1018.5 (n=335)	Total PYE=4591.2 (n=1530)	With continued FIL PYE=2568.5 (n=863)	With de novo FIL PYE=985.2 (n=336)	Total PYE=3553.8 (n=1199)
Most common TEAEs ($\geq 5\%$ in either group)						
COVID-19	145 (12.13) 4.2 (3.5 to 4.9)	41 (12.24) 4.1 (3.0 to 5.6)	186 (12.16) 4.2 (3.6 to 4.8)	80 (9.27) 3.2 (2.5 to 4.0)	36 (10.71) 3.7 (2.6 to 5.2)	116 (9.67) 3.3 (2.8 to 4.0)
Nasopharyngitis	131 (10.96) 4.0 (3.3 to 4.7)	32 (9.55) 3.4 (2.3 to 4.8)	163 (10.65) 3.9 (3.3 to 4.5)	105 (12.17) 4.5 (3.7 to 5.5)	28 (8.33) 3.0 (2.0 to 4.4)	133 (11.09) 4.1 (3.4 to 4.9)
Upper respiratory tract infection	111 (9.29) 3.3 (2.7 to 4.0)	40 (11.94) 4.3 (3.1 to 5.9)	151 (9.87) 3.5 (3.0 to 4.2)	82 (9.50) 3.4 (2.7 to 4.2)	33 (9.82) 3.6 (2.5 to 5.1)	115 (9.59) 3.5 (2.9 to 4.2)
Rheumatoid arthritis (worsening, flare or exacerbation)	87 (7.28) 2.6 (2.1 to 3.2)	29 (8.66) 3.0 (2.0 to 4.3)	116 (7.58) 2.7 (2.2 to 3.2)	103 (11.94) 4.4 (3.6 to 5.3)	30 (8.93) 3.3 (2.2 to 4.6)	133 (11.09) 4.0 (3.4 to 4.8)
Urinary tract infection	103 (8.62) 3.0 (2.5 to 3.7)	35 (10.45) 3.7 (2.6 to 5.1)	138 (9.02) 3.2 (2.7 to 3.8)	69 (8.00) 2.8 (2.2 to 3.6)	30 (8.93) 3.2 (2.2 to 4.6)	99 (8.26) 2.9 (2.4 to 3.6)
Hypertension	71 (5.94) 2.1 (1.6 to 2.6)	29 (8.66) 3.0 (2.0 to 4.3)	100 (6.54) 2.3 (1.8 to 2.8)	66 (7.65) 2.7 (2.1 to 3.4)	28 (8.33) 3.0 (2.0 to 4.4)	94 (7.84) 2.8 (2.2 to 3.4)
Headache	66 (5.52) 1.9 (1.5 to 2.4)	31 (9.25) 3.2 (2.2 to 4.6)	97 (6.34) 2.2 (1.8 to 2.7)	58 (6.72) 2.4 (1.8 to 3.1)	20 (5.95) 2.1 (1.3 to 3.2)	78 (6.51) 2.3 (1.8 to 2.9)
Arthralgia	66 (5.52) 1.9 (1.5 to 2.4)	24 (7.16) 2.5 (1.6 to 3.7)	90 (5.88) 2.0 (1.6 to 2.5)	66 (7.65) 2.7 (2.1 to 3.4)	18 (5.36) 1.9 (1.1 to 3.0)	84 (7.01) 2.5 (2.0 to 3.1)
Latent tuberculosis	66 (5.52) 1.9 (1.5 to 2.5)	13 (3.88) 1.3 (0.7 to 2.2)	79 (5.16) 1.8 (1.4 to 2.2)	45 (5.21) 1.8 (1.3 to 2.4)	26 (7.74) 2.8 (1.8 to 4.1)	71 (5.92) 2.1 (1.6 to 2.6)
Bronchitis	75 (6.28) 2.2 (1.7 to 2.8)	16 (4.78) 1.6 (0.9 to 2.7)	91 (5.95) 2.1 (1.7 to 2.5)	42 (4.87) 1.7 (1.2 to 2.3)	14 (4.17) 1.5 (0.8 to 2.5)	56 (4.67) 1.6 (1.2 to 2.1)
Back pain	53 (4.44) 1.5 (1.1 to 2.0)	17 (5.07) 1.7 (1.0 to 2.8)	70 (4.58) 1.6 (1.2 to 2.0)	43 (4.98) 1.7 (1.2 to 2.3)	17 (5.06) 1.8 (1.0 to 2.9)	60 (5.00) 1.7 (1.3 to 2.2)
TEAEs are defined as any adverse events that began on or after the study drug start date, up to 30 days after permanent discontinuation of study drug. Only adverse events with a start date after LTE treatment start are considered. EAIR, exposure-adjusted incidence rate; FIL(100/200), filgotinib (100 mg/200 mg); LTE, long-term extension; MACE, major adverse cardiovascular events; NMSC, non-melanoma skin cancer; PYE, patient-years of exposure; TEAE, treatment-emergent adverse event; VTE, venous thromboembolism.						

was observed. However, data suggested that events within the serious infections and NMSC categories were mainly driven by COVID-19 and basal carcinoma, respectively. The most common TEAEs occurring in $\geq 5\%$ of patients in either the filgotinib 200 mg or 100 mg groups are listed in table 2.

DISCUSSION

In the FINCH 4 long-term extension study, efficacy was maintained with both filgotinib 200 mg and 100 mg, over the first 156 weeks, in all three patient populations evaluated (methotrexate-IR, bDMARD-IR and methotrexate-naïve patients), both in those who received de novo filgotinib in FINCH 4 and in those who continued filgotinib treatment from the parent study. Similar patterns were seen with the NRI and OC analyses, with higher response rates seen in the OC analysis, as expected. These findings confirm that filgotinib is an effective treatment option for clinically relevant patient populations (those with RA who have not responded adequately or are intolerant to previous DMARDs). Although numerical differences between the two filgotinib doses were observed in the maintenance of remission, the results indicate that filgotinib 100 mg had largely comparable efficacy to the higher dose. This provides reassurance that treatment remains effective in situations where the lower dose is recommended, for example, in those aged 65 years or older, those at increased risk of venous thromboembolism, MACE and malignancy or those with moderate or severe renal impairment.⁵

In addition to measures of disease activity, such as ACR response criteria and DAS28-CRP, we assessed patient-reported outcomes, including pain, which is considered by patients to be a key target of the RA treatment.¹² Pain in RA may result from inflammatory or non-inflammatory pathways, and those who achieve RA remission or low disease activity may continue to experience pain.^{13 14} In addition, early reduction in pain decreases the risk of the development of chronic pain through mechanisms other than nociception alone.¹⁵ Therefore, RA treatments would ideally result in rapid and long-lasting reductions in pain. Results from the current analysis show that improvements in pain from baseline of the parent study were generally maintained throughout FINCH 4. Further, in bDMARD-IR patients who were treated de novo with filgotinib, improvements in pain were seen from FINCH 4 baseline, as early as week 2, demonstrating a rapid effect, which is crucial for long-term pain control. These findings are consistent with a post hoc analysis of FINCH 1, 2 and 3, which demonstrated that filgotinib reduced pain from week 2, with improvements maintained throughout the studies.¹⁶

Efficacy was assessed using DAS28-CRP, CDAI, SDAI and Boolean 1.0 and 2.0 criteria. The proportion of patients in remission remained relatively stable over the long-term extension period. Boolean remission (1.0 and 2.0) was maintained through week 156 of FINCH 4 with

both doses of filgotinib, regardless of whether filgotinib was taken de novo or continued from the parent study. The Boolean 2.0 criteria for remission were developed to address the overly stringent patient global assessment threshold in Boolean 1.0.¹⁰ A validation study by Studenic *et al* confirmed higher remission rates using Boolean 2.0, consistent with SDAI criteria, with no loss of predictive ability in terms of radiographic and functional outcomes.¹⁰ In line with these findings, results from the FINCH 4 study indicate that a higher proportion of patients was classed as being in remission when the Boolean 2.0 versus 1.0 criteria were applied, with ranges in line with those reported by Studenic *et al*.¹⁰ Similarly, data from the FINCH 4 study suggest that CDAI and SDAI remission rates were more closely aligned with Boolean 2.0 than Boolean 1.0 remission rates.

Safety data show that, in general, differences between doses in the EAIR of TEAEs were small, with overlapping 95% CIs. In patients taking de novo filgotinib, the EAIR for all TEAEs was numerically lower in the filgotinib 100 mg group than in the filgotinib 200 mg group. The EAIRs of TEAEs related to study drug and of TEAEs leading to death were numerically higher with filgotinib 200 mg than with filgotinib 100 mg. The EAIRs for the other TEAE categories reported and for TEAEs of interest (serious infection, herpes zoster, adjudicated MACE, adjudicated venous thromboembolic events, malignancy [excluding NMSC] and NMSC) were generally similar between filgotinib doses. Long-term safety data are of particular interest following the results of the ORAL Surveillance study, which showed that, in patients with RA aged 50 years or older with at least one additional cardiovascular risk factor, the incidence of major cardiovascular events and cancer was higher in those treated with tofacitinib than in those treated with a TNF inhibitor.¹⁷ Although no such safety signal was observed in the current analysis from FINCH 4, conclusions cannot be made, owing to the interim nature of the analysis. However, integrated data from the FINCH and DARWIN clinical studies have been reported from 3691 patients with 12 541 PYE to filgotinib. Data showed that, with a median (maximum) exposure of 3.8 (8.3) years, there were small numerical differences between filgotinib doses in the EAIRs of certain adverse events; the EAIRs of NMSC, herpes zoster and all-cause mortality were numerically slightly higher with filgotinib 200 mg than with filgotinib 100 mg, whereas the EAIRs of MACE and serious infections were numerically slightly higher with the lower dose; however, CIs overlapped between the groups.¹⁸ The integrated analysis included the long-term open-label extension study DARWIN 3. Kavanaugh *et al* reported up to 4-year efficacy and safety results from an interim analysis of DARWIN 3, with a focus on safety and adverse events, which were reported in detail.¹⁹

In terms of drug retention, it was observed that approximately 63% of patients remained on the study drug at the time of the analyses. TEAEs leading to an interruption in the study drug occurred in approximately 40% and 36% of patients in the filgotinib 200 mg and 100 mg groups, respectively, whereas TEAEs leading to

premature discontinuation of the study drug occurred in approximately 11% in each treatment group.

There are several limitations associated with this analysis. There was no control group in the long-term extension study. In addition, long-term extension studies may be biased towards patients who respond to treatment; however, an NRI analysis was used to provide a conservative estimate of binary outcomes, classing those with missing data as non-responders. Patients were originally enrolled in randomised clinical trials with inclusion and exclusion criteria, which may not be representative of all patients in clinical practice. However, enrolling patients from FINCH 1 and 2 meant both methotrexate-IR and bDMARD-IR subgroups were included in the analysis, representing clinically relevant patient populations. Real-world efficacy data from a larger patient population will provide valuable insights beyond those obtained from clinical trials. Such real-world data will be provided by the ongoing phase 4, non-interventional FILOSOPHY study²⁰ evaluating filgotinib for the treatment of RA in routine clinical practice. Another limitation is that as this is an interim analysis, not all data sets are available. Once the FINCH 4 study is complete, it will be important to interpret results based on EULAR recommendations for the reporting of long-term extension studies in rheumatology,²¹ for example, by including additional data and analyses from all patients over time, from baseline of the parent trial to the end of FINCH 4. While OC analyses have been included, NRI analyses, as the more stringent, are the focus of this interim analysis, to present a conservative approach to the reporting of efficacy data.

In conclusion, interim efficacy results from the FINCH 4 study confirm that beneficial effects of filgotinib 100 mg and 200 mg on disease activity measures were maintained up to week 156, independent of the initial background treatment (methotrexate-IR, bDMARD-IR and methotrexate-naïve groups). When Boolean 2.0 rather than Boolean 1.0 criteria were applied, remission rates were numerically higher and were more comparable with those reported using index-based criteria. Safety data observed during the long-term extension were in line with the known safety profile for filgotinib.

Author affiliations

¹Centre for Musculoskeletal Research, University of Manchester, Manchester, UK

²NIHR Manchester Biomedical Research Centre, Manchester, UK

³Division of Rheumatology, Medical University of Vienna, Vienna, Austria

⁴Rheumatology, Montpellier University, Montpellier, Occitanie, France

⁵University of Occupational and Environmental Health Japan, Kitakyushu, Japan

⁶University of Milan, Milan, Italy

⁷ASST Gaetano Pini-CTO, Milan, Italy

⁸Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig Maximilian University of Munich, Munich, Germany

⁹Keio University, Tokyo, Japan

¹⁰Saitama Medical University, Saitama, Japan

¹¹Rheumatology, Strasbourg University Hospitals, Strasbourg, Grand Est, France

¹²Immunopathology group, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain

¹³Department of Rheumatology, KU Leuven and University Hospital Leuven, Leuven, Belgium

¹⁴ARS Rheumatica, Warsaw, Poland

¹⁵Galapagos GmbH, Basel, Switzerland

¹⁶Galapagos NV, Mechelen, Belgium

¹⁷University of Leeds, Leeds, UK

¹⁸NIHR Leeds Biomedical Research Centre, Leeds, UK

Acknowledgements We thank the physicians and patients who participated in these studies, and Benjamin Pett and Machiel Visser (Galapagos NV, Mechelen, Belgium) for their support with programming to prepare analysis datasets and source tables. Medical writing support was provided by Debbie Sherwood, BSc, CMPP (Aspire Scientific Ltd, Bollington, UK), and funded by Galapagos NV (Mechelen, Belgium). Publication coordination was provided by Jo-Ann E. West, MSc, a consultant funded by Galapagos NV. Results from the analysis were previously presented at EULAR 2023: Buch MH, Aletaha D, Caporali R, et al. POS0853 Efficacy of filgotinib in patients with rheumatoid arthritis: week 156 results from a long-term extension study. *Ann Rheum Dis* 2023;82:729–30.

Contributors FDL, EVEO and VR were involved in the concept or design or work; EVEO was involved with the analysis of data for the work; all authors were involved with the interpretation data and read and approved the final version of the manuscript. FDL acts as the guarantor of the study.

Funding The FINCH studies were co-funded by Gilead Sciences (Foster City, CA, USA) and Galapagos NV (Mechelen, Belgium).

Competing interests MHB reports consultancy fees from AbbVie, Boehringer Ingelheim, CESAS Medical, Galapagos, Gilead and Pfizer (all paid to host institution); speaker fees from AbbVie (paid to host institution); and grant/research support from Gilead (paid to host institution). DA reports consultancy fees, speaker fees and grant/research support from AbbVie, Eli Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, Sandoz and Sanofi. BGC reports consultancy fees from AbbVie, Celltrion, Eli Lilly, Galapagos, Gilead, Janssen and Roche-Chugai; and speaker fees from AbbVie, Celltrion, Eli Lilly, Galapagos, Janssen, Pfizer and Roche-Chugai. YT reports speaker fees and/or honoraria from AbbVie, Asahi Kasei, AstraZeneca, Boehringer Ingelheim, BMS, Chugai, Eli Lilly, Eisai, Gilead, GSK, Pfizer, Taisho and Taiho; and research grants from Asahi Kasei, Chugai, Eisai, Mitsubishi Tanabe and Taisho. RC reports consultancy fees from AbbVie, Accord, Eli Lilly, Fresenius Kabi, Galapagos, MSD, Novartis, Pfizer and UCB; and speaker fees from AbbVie, Amgen, BMS, Celltrion, Eli Lilly, Fresenius Kabi, Galapagos, Janssen, MSD, Novartis, Pfizer and UCB. HS-K reports consultancy fees and speaker fees from AbbVie, Eli Lilly, Galapagos and Pfizer. TT reports consultancy fees from AbbVie, Astellas Pharma, Eli Lilly Japan and Gilead; and speaker fees and/or honoraria from AbbVie, Astellas Pharma, Eisai, Eli Lilly Japan, Gilead and Pfizer Japan. J-EG reports consultancy fees from AbbVie, BMS, Eli Lilly, Galapagos, Gilead, MSD, Novartis and Pfizer; and grant/research support from AbbVie, BMS, Lilly and Pfizer. RB reports consultancy fees from AstraZeneca, Galapagos, Janssen, Novartis and Pfizer; speaker fees from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche and Sanofi; and grant/research support from AbbVie and Roche. PV reports consultancy fees from Celltrion, Eli Lilly, Galapagos, Gilead, Nordic Pharma and Sidekick Health; speaker fees from AbbVie, Eli Lilly, Galapagos and Roularta; and grant/research support from Galapagos and Pfizer. AZ-S has no disclosures of interest to report. FDL is a former employee of, and shareholder in, Galapagos. EVEO reports consultancy fees from Galapagos and Janssen and is a shareholder in UCB. VR is a former employee of Galapagos and current employee of GSK Vaccines. PE reports consultancy fees from AbbVie, BMS, Boehringer Ingelheim, Eli Lilly, Galapagos, Gilead and Novartis; speaker fees from AbbVie, Boehringer Ingelheim, Eli Lilly, Gilead, Novartis and Samsung; and grant/research support from AbbVie, BMS, Eli Lilly and Samsung.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation Good Clinical Practice guidelines. FINCH 1 was approved by the Advarra Central Institutional Review Board (Reference # 00000971). FINCH 2 was approved by the Administrative Panel on Human Subjects in Medical Research (Reference # 4593). FINCH 3 was approved by Ethics Committee Research UZ/KU Leuven (Reference # S59627). The study protocol was approved by the international review board or ethics committee at each study site, and all patients provided written informed consent. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Anonymised individual patient data will be shared upon request for research purposes, dependent upon the nature of the request, the merit of the proposed research and the availability of the data and their intended use. The full data-sharing policy for Gilead Sciences, Inc. can be found at <https://www.gilead.com/about/ethics-and-code-of-conduct/policies>. Data-sharing policy for Galapagos NV can be found at <https://www.clinicaltrials-glpg.com/us/en/data-transparency.html>.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Maya H Buch <http://orcid.org/0000-0002-8962-5642>
Daniel Aletaha <http://orcid.org/0000-0003-2108-0030>
Bernard G Combe <http://orcid.org/0000-0003-4002-1861>
Yoshiya Tanaka <http://orcid.org/0000-0002-0807-7139>
Hendrik Schulze-Koops <http://orcid.org/0000-0002-1681-491X>
Tsutomu Takeuchi <http://orcid.org/0000-0003-1111-8218>
Jacques-Eric Gottenberg <http://orcid.org/0000-0002-9469-946X>
Ricardo Blanco <http://orcid.org/0000-0003-2344-2285>
Patrick Verschuere <http://orcid.org/0000-0002-0340-3580>
Paul Emery <http://orcid.org/0000-0002-7429-8482>

REFERENCES

- Shams S, Martinez JM, Dawson JRD, et al. The therapeutic landscape of rheumatoid arthritis: current state and future directions. *Front Pharmacol* 2021;12:680043.
- van Vilsteren M, Boot CRL, Knol DL, et al. Productivity at work and quality of life in patients with rheumatoid arthritis. *BMC Musculoskelet Disord* 2015;16:107.
- Smolen JS, Landewé RBM, Bijlsma JWW, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis* 2020;79:685–99.
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2021;73:924–39.
- Jyseleca Summary of Product Characteristics, Available: https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf
- Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. *Ann Rheum Dis* 2021;80:848–58.
- Genovese MC, Kalunian K, Gottenberg J-E, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. *JAMA* 2019;322:315–25.
- Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. *Ann Rheum Dis* 2021;80:727–38.
- Winthrop KL, Tanaka Y, Takeuchi T, et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. *Ann Rheum Dis* 2022;81:184–92.
- Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. *Ann Rheum Dis* 2023;82:74–80.
- Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). *Am J Epidemiol* 1990;131:373–5.
- Taylor P, Manger B, Alvaro-Gracia J, et al. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. *J Int Med Res* 2010;38:1213–24.
- Ishida M, Kuroiwa Y, Yoshida E, et al. Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. *Mod Rheumatol* 2018;28:789–99.
- Simon LS, Taylor PC, Choy EH, et al. The Jak/STAT pathway: a focus on pain in rheumatoid arthritis. *Semin Arthritis Rheum* 2021;51:278–84.
- Pazmino S, Boonen A, De Cock D, et al. Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial. *RMD Open* 2021;7:e001615.
- Taylor PC, Kavanaugh A, Nash P, et al. Impact of filgotinib on pain control in the phase 3 FINCH studies. *RMD Open* 2024;10:e003839.
- Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. *New Engl J Med* 2022;386:1766–8.
- Winthrop K, Aletaha D, Caporali R, et al. POS0844 Integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis with a maximum exposure of 8.3 years. *Ann Rheum Dis* 2023;82:721–2.
- Kavanaugh A, Westhovens RR, Winthrop KL, et al. Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of Phase II rheumatoid arthritis programs. *J Rheumatol* 2021;48:1230–8.
- Galloway J, Bevers K, Verschuere P, et al. P118 Baseline characteristics of and early outcomes in the first 200 patients with rheumatoid arthritis treated with filgotinib in a prospective observational study. *Rheumatology* 2023;62:kead104.159.
- Buch MH, Silva-Fernandez L, Carmona L, et al. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. *Ann Rheum Dis* 2015;74:963–9.